Ovarian Steroid Mechanisms in Premenstrual Exacerbation of Depression and Suicide Risk

Grand Rounds

Event Info


  1. Events
  2. Grand Rounds
  3. Ovarian Steroid Mechanisms in Premenstrual Exacerbation...

Ovarian Steroid Mechanisms in Premenstrual Exacerbation of Depression and Suicide Risk


Event Info
Category Date and Time
  • Wednesday, October 02, 2019
  • 01:00 PM - 02:00 PM
Topic and Speaker
  • Ovarian Steroid Mechanisms in Premenstrual Exacerbation of Depression and Suicide Risk
  • Tory Eisenlohr-Moul PhD
    • Assistant Professor of Psychiatry and Psychology
    • Associate Director of Translational Research in Women’s Mental Health
    • Department of Psychiatry
    • University of Illinois at Chicago College of Medicine
    Tory Eisenlohr-Moul

  • School of Public Health / Psychiatric Institute (SPHPI)
  • 1601 W. Taylor St.
  • Chicago IL 60612
Conference Room
  • 109 (Auditorium)
Video Recording
Event Details

Dr. Eisenlohr-Moul received her PhD in Clinical Psychology in 2014 from the University of Kentucky, where her training emphasized translational clinical science, endocrine and immune factors in psychopathology, and advanced statistics. She completed her clinical internship at Duke University Medical Center from 2013-2014 in full-model Dialectical Behavior Therapy, a highly-structured, evidence-based treatment for adults presenting with chronic suicidality. From 2014-2017, Dr. Eisenlohr-Moul received intensive postdoctoral training in the pathophysiology of reproductive mood disorders (premenstrual dysphoric disorder, perinatal mood disorder, and perimenopausal mood disorder) at the Center for Women’s Mood Disorders at the University of North Carolina at Chapel Hill. She received a prestigious K99/R00 award from the National Institute of Mental Health in 2016. Dr. Eisenlohr-Moul joined the Women’s Mental Health Research Program in January 2018 with completion of an R00-funded experiment.

Dr. Eisenlohr-Moul is a clinical scientist studying emotional, cognitive and behavioral responses to changing hormones across the menstrual cycle. Primary outcomes of interest are suicidality, substance abuse, and dysregulated interpersonal functioning (e.g., the interpersonal symptoms of borderline personality disorder or BPD). 

The first focus of the Eisenlohr-Moul laboratory is the use of experimental clinical trial methods to examine the effects of perimenstrual withdrawal from estradiol, progesterone, and their neurosteroid metabolites (e.g., allopregnanolone) on acute suicide risk. Early experimental data from Dr. Eisenlohr-Moul’s K99 award indicates that perimenstrual hormone stabilization (vs. withdrawal under placebo) prevents perimenstrual risk for acute suicidality. Further work will compare the effects of estradiol and progesterone stabilization, and will probe various potential neurobiological mediators of these experimental effects. This program of research may help to clarify the basic neurobiological mechanisms of acute changes in suicide risk for both females and males, and may eventually lead to the development of treatments that anticipate and prevent suicide attempts among at-risk individuals. 

The second focus of the laboratory is the identification, characterization, and reliable diagnosis of subtypes of psychiatric symptom change across the menstrual cycle. At the diagnostic level, this includes the development of reliable methods for differential diagnosis of (1) the new DSM-5 diagnosis of premenstrual dysphoric disorder (PMDD), (2) perimenstrual exacerbation of underlying psychiatric disorder (e.g., BPD), and (3) PMDD with comorbid psychiatric diagnoses. During her fellowship in reproductive mood disorders, Dr. Eisenlohr-Moul developed and published the Carolina Premenstrual Assessment Scoring System (or C-PASS), the first fully standardized computerized method for making the new DSM-5 diagnosis of Premenstrual Dysphoric Disorder using two months of daily symptom ratings. Dr. Eisenlohr-Moul also works with large observational datasets of daily symptom data to examine potential symptom timing subgroups within each of these diagnostic categories that may help to clarify individual differences in the pathophysiologic underpinnings of perimenstrual symptoms that cut across the above diagnostic categories (e.g., early luteal vs. late luteal symptom onset). This work may inform the development of targeted treatments based on the reliable assessment of individual differences in perimenstrual symptom change dynamics. 


Psychiatrists, Neurologists, and other affiliated professionals interested in mental health


To provide current information on research, treatment, and policy issues relating to psychiatry and its adjunct fields

Instructional level:



  1. Define premenstrual dysphoric disorder (PMDD) and premenstrual exacerbation (PME) of depression
  2. Describe at least one hormonal mechanism of PMDD and PME
  3. Specify the first, second, and third line evidence-based treatments for premenstrual disorders

The University of Illinois at Chicago (UIC) College of Medicine is accredited by the Accreditation Council for Continuing Medical Education ACCME) to provide continuing medical education for physicians.

The University of Illinois at Chicago (UIC) College of Medicine designates this live activity for a maximum of 1credit AMA PRA Category 1 credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Continuing Education Units (1) will be available for Social Workers and affiliated reciprocal agencies. Illinois Board License number 159-000112.

The Department of Psychiatry at the University of Illinois at Chicago is approved by the American Psychological Association to sponsor continuing education for psychologists.  The Department of Psychiatry at the University of Illinois at Chicago maintains responsibility for this program and its content. This event is 1 credit hour continuing education.

No member of the planning committee for this activity have reported a relevant relationship with a commercial interest.  There is no conflict of interest and nothing to disclose.

Dr. Tory Eisenlohr-Moul has no relevant financial relationship with commercial interests related to this CME activity.